S-606001 add-on to enzyme replacement therapy in adults with late-onset Pompe disease

Phase 2, randomised, double-blind trial in Pompe disease comparing S-606001 + enzyme replacement therapy with Placebo + enzyme replacement therapy (2 arms). Primary endpoint: Change from baseline in percent predicted forced vital capacity at 52 weeks. Planned start Feb 2026; status: authorised.